Halberd (Halberd) EPS (Diluted) : $ (TTM As of Jul. 2023)

View and export this data going back to 2009. Start your Free Trial

What is Halberd EPS (Diluted)?

Halberd's Earnings per Share (Diluted) for the six months ended in Jul. 2023 was $-0.00.

Halberd's EPS (Basic) for the six months ended in Jul. 2023 was $-0.00.

Halberd's EPS without NRI for the six months ended in Jul. 2023 was $-0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

Halberd EPS (Diluted) Historical Data

The historical data trend for Halberd's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Halberd EPS (Diluted) Chart

Halberd Annual Data

Trend

Jul08

Jul22

Jul23

EPS (Diluted)

Halberd Semi-Annual Data
	Jul08	Jul22	Jul23
EPS (Diluted)	-	-	-

Competitive Comparison of Halberd's EPS (Diluted)

For the Biotechnology subindustry, Halberd's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Halberd's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Halberd's PE Ratio distribution charts can be found below:

* The bar in red indicates where Halberd's PE Ratio falls into.

Halberd EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Halberd's Diluted EPS for the fiscal year that ended in Jul. 2023 is calculated as

Diluted EPS (A: Jul. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-0.454	-	0)	/	537.108
	=	-0.00

Halberd's Diluted EPS for the quarter that ended in Jul. 2023 is calculated as

Diluted EPS (Q: Jul. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-0.454	-	0)	/	537.108
	=	-0.00

Halberd (OTCPK:HALB) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Halberd EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Halberd's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.

Halberd (Halberd) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Halberd Corp (OTCPK:HALB) » Definitions » EPS (Diluted)

Comparable Companies

Traded in Other Exchanges

N/A

Address

P.O. Box 25, Jackson Center, PA, USA, 16133

Website

https://www.halberdcorporation.com

Halberd Corp is a research-based biotechnology company seeking to discover and develop medical treatments for a range of diseases. The Company's extracorporeal treatment is designed to treat hard-to-cure blood-borne, neurologic and infectious diseases. The Company's patented methodology removes the appropriate bodily fluid from the patient, in a continuous fashion, like dialysis, or in a batch process, like blood sample testing.

Executives

John Christopher Maddox	director, 10 percent owner, officer: President, COO, Treasurer and, other: Interim CFO	10755 VERNON, HUNTINGTON WOODS MI 48070
Mark Sven Lundquist	director, 10 percent owner, officer: CEO, Secretary and Director	24655 TUDOR LANE, FRANKLIN MI 48025
Cocco Nicholas A. Jr.	director	50104 N. JIMMY COURT, CHESTERFIELD MI 48047-1898
Leland Michael Thomas	director	280 LASALLE PLACE, GROSSE POINTE FARMS MI 88236